Pharmacology Discovery Services Taiwan, LTD.

Pharmacology Discovery Services Taiwan, LTD. is a for-profit Taiwanese corporate entity registered in the U.S. federal government's System for Award Management (SAM) since April 2017, with registration valid through February 2026. The company specializes in providing preclinical infectious disease research services, particularly focusing on developing and supplying advanced animal models for scientific research and medical countermeasure testing. Specifically, Pharmacology Discovery Services Taiwan designs and produces murine (mouse) models that simulate various bacterial infections, which are critical for understanding disease mechanisms and evaluating potential therapeutic treatments.

The company has consistently secured federal contract delivery orders from the National Institute of Allergy and Infectious Diseases (NIAID), primarily providing preclinical models of infectious diseases. Their contract work has specifically involved creating specialized animal models for research, including mouse models of Neisseria gonorrhoeae infection, bacterial infection models, and models of antibiotic-resistant urinary tract infections. These delivery orders have ranged in value from $288,577 to $1,872,088, all issued under the NIAID Preclinical Models of Infectious Diseases 2017-2024 indefinite-delivery/indefinite-quantity (IDIQ) contract vehicle. Notably, none of their awards have included set-aside designations, and all work has been performed in Taiwan, supporting NIAID's infectious disease research mission by providing critical preclinical testing capabilities.

Pharmacology Discovery Services Taiwan holds a single-award Indefinite Delivery Contract with NIAID, valued up to $146.3 million and running through July 2031. This comprehensive contract supports preclinical infectious disease research by providing a wide range of animal and animal replacement models for screening and evaluating medical countermeasures such as therapeutics, vaccines, and diagnostics. The contract's primary objective is to bridge the gap between in vitro testing and clinical evaluation by developing refined preclinical models that can assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of potential medical interventions. Through this contract, the company continues to supply diverse animal models representing human infectious diseases, with a particular emphasis on bacterial infections, urinary tract infections, and models focusing on priority pathogens.